Press Releases

GlobeNewswire, Inc.

– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and...

GlobeNewswire, Inc.

SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that...

GlobeNewswire, Inc.

WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases, today announced it has...

DVIDS - Georgia

RAMSTEIN AIR BASE, Germany —Standing inside a military aircraft, U.S. and Tanzanian medical professionals worked through a problem that could someday become very real: how to safely move a seriously ill or injured patient through the air. Where...

GlobeNewswire, Inc.

Ronkonkoma, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Qosina, a global supplier of stock components, custom solutions and regulatory services for the medical device and life sciences industries, is proud to sponsor BayCath Medical’s Innovation Week,...

EIN Presswire

Joint research program will evaluate three non-hallucinogenic psychedelic-inspired compounds designed to replicate psilocybin's therapeutic effects TORONTO, ON, CANADA, October 13, 2026 /⁨EINPresswire.com⁩/ -- Jocasta Neuroscience, Inc. (“Jocasta”...

GlobeNewswire, Inc.

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) is pleased to announce that its wholly owned subsidiary, HealthTab Ltd. (“HealthTab”), has completed an integration with...

GlobeNewswire, Inc.

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of...

GlobeNewswire, Inc.

First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum Record First-Quarter Net Revenue of $257 Million, Up 23%...

EIN Presswire

Named clinician editors and AI agents build and fact-check one medical knowledge base, so every answer can be traced to a source and stays current.

EIN Presswire

A closer look at five China-based manufacturers supporting efficient and consistent tablet production for pharmaceutical applications.

GlobeNewswire, Inc.

Approximately $28 million in planned TRUKING equipment advances domestic manufacturing capacity, strengthens the Company’s preparedness strategy, and supports new commercial opportunities SPRING BRANCH, Texas, Oct. 08, 2026 (GLOBE NEWSWIRE) --...

EIN Presswire

The Business Research Company’s Recent Ultra Pure Water Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 13, 2026 /⁨EINPresswire.com⁩/ -- The ultra pure water market is...

EIN Presswire

New guides cover 2027 Medicare Advantage and Part D changes, plus how the ACA affects Medicare eligibility.

GlobeNewswire, Inc.

- Repayment of Existing Loan Facility Completed - - Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End 2026 and Topline Data in H1...

GlobeNewswire, Inc.

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Medicovestor, Inc. today announced FDA clearance of its Investigational New Drug (IND) application for MC001, the Company's first-in-class dimeric chemoimmunotherapy ADC for pancreatic cancer, following...

GlobeNewswire, Inc.

TRIV-573, potential first-in-class KLK5/7 x IL-13 bispecific, simultaneously targets skin barrier dysfunction and inflammation to address fundamental drivers of disease Company also announces the completion of a strategic transaction to advance...

Mississippi State Department of Health

This page has been automatically translated from English.

GlobeNewswire, Inc.

Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026 The collaboration is underpinned by pre-clinical data that...

GlobeNewswire, Inc.

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers Selected as one of the Top 150 Abstracts at the Society for...